¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦21Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2023-05-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦21Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2023-05-19
±³À°ÀÏÀÚ : 2023-05-19
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ¼­¿ï

±³À°ÁÖÁ¦ : 2023³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦21Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ

ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ±è¿¹Áö
¿¬¶ôó : 070-4367-2707  

À̸ÞÀÏ : meetings@ksmo.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ

¼¼ºÎ¼ö°­·á : 80,000¿ø  

ºñ°í "(ȸ¿ø) -Á¤È¸¿ø 40,000 60,000 -ÁØȸ¿ø 30,000 50,000 (ºñȸ¿ø) -±³¼ö, Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø 50,000 70,000 -ÀüÀÓÀÇ, Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý 30,000 50,000 -¾÷ü Âü°¡ 60,000 80,000"

±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 09:00~09:40 Novel approaches to tailoring therapy for typical and atypical EGFR mutations John Heymach(MDACC)

Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 09:40~09:50 Discussion ( )

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 10:00~10:20 Case sharing  KOSMOS molecular tumor board ¹Ú¼÷·Ã(¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 10:20~10:40 Liquid biopsy-guided basket trial -are we ready?  : Overview ±èÅ¿ë(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 10:40~11:00 Liquid biopsy-guided basket trial -are we ready? : Technical aspects and limitations °ø¼±¿µ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 11:00~11:20 An updated consensus on the use of NGS in patients with advanced cancer : A joint report  KSMO and KSP ±è¹Ì¼Ò(¼­¿ï´ëº´¿ø Á¾¾ç³»°ú)

Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 11:20~11:30 Discussion ( )

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 11:30~12:10 Landmark Clinical Trials Guiding the Current Clinical Practice in Adjuvant Treatment for Resectable Gastric Cancer °­¿ø±â(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 12:20~13:00 Pembrolizumab for the treatment of thoracic malignancies, Lung, Head and Neck, and Esophageal cancer È«¹ÎÈñ(¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿¬¼¼¾Ïº´¿ø)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 13:00~13:20 Ç×¾ÏÁ¦ °¡Ä¡Æò°¡ ±âÁØ, ¿Ü±¹ Æò°¡ ±âÁØ°ú Çѱ¹(Value framework (ASCO), MCBS (ESMO), Korean) °­ÁøÇü(Ä«Å縯´ëÇб³¼º¸ðº´¿ø)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 13:20~13:40 Ç×¾ÏÁ¦ °¡Ä¡ Æò°¡ ±âÁØ, ½Å¾à µîÀç °úÁ¤¿¡¼­ÀÇ Àû¿ë, »ç·Ê ¹× ¹®Á¦Á¡ ±è±¹Èñ(½ÉÆò¿ø ¾àÁ¦°ü¸®½Ç, ½Å¾àµîÀçºÎ)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 13:40~14:00 Çã°¡ ÃÊ°ú ÀǾàÇ°ÀÇ ºñ±Þ¿© »ç¿ë, »çÀü ½ÅûÀÇ ±Ù°Å¿Í ÀÓ»ó¿¡¼­ÀÇ ÇÑ°è ÀÌÀç·Ã(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 14:00~14:20 Çã°¡ ÃÊ°ú ÀǾàÇ°ÀÇ ºñ±Þ¿© »ç¿ë¿¡ ´ëÇÑ ¾ÏÁúȯ ½ÉÀÇÀ§¿øȸÀÇ Æò°¡ ±âÁØ°ú °³¼± ¹æ¾È ÀÓÈ£¿µ(¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø, ¾ÏÁúȯ½ÉÀÇÀ§¿øȸÀå)

Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 11:20~11:30 Discussion ( )

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 14:40~15:00 Predicting response to immunotherapy using single cell genomics ±èÇý·Ã(¿¬¼¼¼¼ºê¶õ½º)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 15:00~15:20 AI-based biomarkers predicting clinical outcomes of immuno-oncology agents ¿ÁÂù¿µ(·ç´Ö)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 15:20~15:40 Predicting the efficacy and toxicity of immunotherapy using blood samples  patients ÀüÈ«Àç(ºÐ´çÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 15:40~16:00 Maximizing the therapeutic efficacy of immunotherapy through T cell characterization analysis ½ÅÀÇö(Ä«À̽ºÆ®)

Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 16:00~16:10 Discussion ( )

±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 16:10~16:50 How to build a international collaboration: experience of ESMO Asia Ravindran Kanesvaran(Deputy Chair and Senior Consultant , Division of Medical Oncology, National Cancer Centre Singapore)

Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 16:50~17:00 Discussion ( )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦21Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2023-05-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023 ´ëÀü±¤¿ª½ÃÀÇ»çȸ Ãá°è Çмú´ëȸ : 2023-05-20
´ÙÀ½±Û ´ëÇÑ»óºÎÀ§Àå°ü¡¤Ç︮ÄÚ¹ÚÅÍÇÐȸ ´ë±¸°æºÏÁöȸ ½ÉÆ÷Áö¿ò(1ÀÏÂ÷) : 2023-05-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 45 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 35 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 36 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 44 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 38 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 29 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 12 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 12 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 26 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 14 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 12 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 32 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 23 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 26 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 22 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷